HIV molecular immunology database

 

Search the Epitope Variant and Escape Mutation Database

Help


Found 1 matching record:

Displaying record number 61555

HXB2 Location  Pol(330-338)   Pol Epitope Map
View variants at this location
Epitope NPEIVIYQY   Epitope Alignment
Variants
NPEIVIiQY   diminished response; susceptible form
NPEIVIvQY   diminished response; susceptible form
NPEIVIcQY   diminished response; susceptible form
Epitope Name NY9
Species (MHC/HLA human(B*3501)

Variant Details

Showing all: 3 variant(s).


Variant ID.  3962
Epitope Seq.  NPEIVIYQY
Variant Seq.  NPEIVIiQY
Mutations Y/I
Epitope Location Y7I
HXB2 Location Y336I
Mutation Type DR: diminished response
SF: susceptible form
Epitope Subtype CRF01_AE
Variant Subtype CRF01_AE
Method CD8 T-cell Elispot - IFNy, Chromium-release assay, Intracellular cytokine staining
Note Subtype A/E's NY9-3E mutant, NY9-3E7I, was cross-recognized by CTL from 3 Japanese A/E-infected subjects (KI-667, KI-805, KI-1124). NY9-3E-specific CTL from KI-667 recognized NY9-3E7I peptide as well as they did WT NY9-3E, but KI-667's CTL had lower cytotoxic ability against cells infected with mutant 7I. NY9-3E-specific CTL from KI-805 recognized NY9-3E7I peptide more strongly than WT but 7I-infected cells were recognized similarly to WT. Affinity of NY9-3E7I was greater for HLA-B*3501 when compared to WT NY9-3E.


Variant ID.  3963
Epitope Seq.  NPEIVIYQY
Variant Seq.  NPEIVIvQY
Mutations Y/V
Epitope Location Y7V
HXB2 Location Y336V
Mutation Type DR: diminished response
SF: susceptible form
Epitope Subtype CRF01_AE
Variant Subtype CRF01_AE
Method CD8 T-cell Elispot - IFNy, Chromium-release assay, Intracellular cytokine staining
Note Subtype A/E's NY9-3E mutant, NY9-3E7V, was cross-recognized by CTL from 3 Japanese A/E-infected subjects (KI-667, KI-805, KI-1124). NY9-3E-specific CTL from KI-667 recognized NY9-3E7V peptide more weakly than WT NY9-3E, and KI-667's CTL had lower cytotoxic ability against cells infected with mutant 7V. NY9-3E-specific CTL from KI-805 recognized NY9-3E7V peptide as well as 7V-infected cells more strongly than WT . Affinity of NY9-3E7V was greater for HLA-B*3501 when compared to WT NY9-3E.


Variant ID.  3964
Epitope Seq.  NPEIVIYQY
Variant Seq.  NPEIVIcQY
Mutations Y/C
Epitope Location Y7C
HXB2 Location Y336C
Mutation Type DR: diminished response
SF: susceptible form
Epitope Subtype CRF01_AE
Variant Subtype CRF01_AE
Method CD8 T-cell Elispot - IFNy, Chromium-release assay, Intracellular cytokine staining
Note Subtype A/E's NY9-3E mutant, NY9-3E7C, was cross-recognized by CTL from 3 Japanese A/E-infected subjects (KI-667, KI-805, KI-1124). NY9-3E-specific CTL from KI-667 recognized NY9-3E7C peptide more weakly than WT NY9-3E, and KI-667's CTL had lower cytotoxic ability against cells infected with mutant 7C. NY9-3E-specific CTL from KI-805 recognized NY9-3E7C peptide as well as 7C-infected cells more weakly than WT . Affinity of NY9-3E7C was greater for HLA-B*3501 when compared to WT NY9-3E.

References

Kuse2015 Nozomi Kuse, Mohammad Arif Rahman, Hayato Murakoshi, Giang Van Tran, Takayuki Chikata, Madoka Koyanagi, Kinh Van Nguyen, Hiroyuki Gatanaga, Shinichi Oka, and Masafumi Takiguchi. Different Effects of Nonnucleoside Reverse Transcriptase Inhibitor Resistance Mutations on Cytotoxic T Lymphocyte Recognition between HIV-1 Subtype B and Subtype A/E Infections. J. Virol., 89(14):7363-7372, Jul 2015. PubMed ID: 25972553. Show all entries for this paper.


Questions or comments? Contact us at immuno@lanl.gov
 
Operated by Los Alamos National Security, LLC, for the U.S. Department of Energy's National Nuclear Security Administration
Copyright © 2006-2017 LANS LLC All rights reserved | Disclaimer/Privacy

Dept of Health & Human Services Los Alamos National Institutes of Health